WO2016201365A3 - Procédés pour le traitement de cancers - Google Patents

Procédés pour le traitement de cancers Download PDF

Info

Publication number
WO2016201365A3
WO2016201365A3 PCT/US2016/037078 US2016037078W WO2016201365A3 WO 2016201365 A3 WO2016201365 A3 WO 2016201365A3 US 2016037078 W US2016037078 W US 2016037078W WO 2016201365 A3 WO2016201365 A3 WO 2016201365A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
tosedostat
gene expression
expression profile
treating cancers
Prior art date
Application number
PCT/US2016/037078
Other languages
English (en)
Other versions
WO2016201365A2 (fr
Inventor
Giuseppe VISANI
Pier Paolo PICCALUGA
Alessandro ISIDORI
Original Assignee
Visani Giuseppe
Piccaluga Pier Paolo
Isidori Alessandro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visani Giuseppe, Piccaluga Pier Paolo, Isidori Alessandro filed Critical Visani Giuseppe
Publication of WO2016201365A2 publication Critical patent/WO2016201365A2/fr
Publication of WO2016201365A3 publication Critical patent/WO2016201365A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés pour le traitement d'un cancer, tel qu'un cancer hématologique ou une tumeur solide, comprenant l'exécution d'une analyse du profil d'expression génique d'un échantillon biologique (par exemple, un échantillon de moelle osseuse, de sang ou d'une tumeur) et l'administration de tosedostat lorsque le profil d'expression génique indique la probabilité d'une réponse clinique pour le traitement.<i /> Dans certains modes de réalisation, le tosedostat est administré en combinaison avec un ou plusieurs agents antinéoplasiques supplémentaires.
PCT/US2016/037078 2015-06-12 2016-06-10 Procédés pour le traitement de cancers WO2016201365A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562175100P 2015-06-12 2015-06-12
US62/175,100 2015-06-12

Publications (2)

Publication Number Publication Date
WO2016201365A2 WO2016201365A2 (fr) 2016-12-15
WO2016201365A3 true WO2016201365A3 (fr) 2017-01-19

Family

ID=57504543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/037078 WO2016201365A2 (fr) 2015-06-12 2016-06-10 Procédés pour le traitement de cancers

Country Status (1)

Country Link
WO (1) WO2016201365A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113683699B (zh) * 2017-06-22 2023-04-18 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
EP3735590A1 (fr) * 2018-01-04 2020-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pour le traitement d'un mélanome résistant
CN110923319B (zh) * 2019-12-20 2023-09-12 华中科技大学同济医学院附属同济医院 Ptpre作为靶标在制备或筛选抗肝癌药物中的用途及其相关药物
US20220031668A1 (en) * 2020-07-29 2022-02-03 University Of Kentucky Research Foundation Methods of inhibiting procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2
CN112280865B (zh) * 2020-11-17 2022-05-27 圣湘生物科技股份有限公司 一种用于检测肝癌的试剂组合，试剂盒及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080305965A1 (en) * 2004-02-23 2008-12-11 Erasmus Universiteit Rotterdam Classification, Diagnosis and Prognosis of Acute Myeloid Leukemia by Gene Expression Profiling
US20120070450A1 (en) * 2009-03-24 2012-03-22 Riken Leukemia stem cell markers
US20120082993A1 (en) * 2002-11-15 2012-04-05 Morehouse School Of Medicine Detecting cancer with anti-cxcl16 and anti-cxcr6 antibodies
WO2013166558A1 (fr) * 2012-05-11 2013-11-14 Clinical Genomics Pty Ltd Groupe de marqueurs génétiques diagnostiques destiné au cancer colorectal

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120082993A1 (en) * 2002-11-15 2012-04-05 Morehouse School Of Medicine Detecting cancer with anti-cxcl16 and anti-cxcr6 antibodies
US20080305965A1 (en) * 2004-02-23 2008-12-11 Erasmus Universiteit Rotterdam Classification, Diagnosis and Prognosis of Acute Myeloid Leukemia by Gene Expression Profiling
US20120070450A1 (en) * 2009-03-24 2012-03-22 Riken Leukemia stem cell markers
WO2013166558A1 (fr) * 2012-05-11 2013-11-14 Clinical Genomics Pty Ltd Groupe de marqueurs génétiques diagnostiques destiné au cancer colorectal

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEVIS, M: "FLT3 Mutations in Acute Myeloid Leukemia: What is the Best Approach in 2013?", ASH EDUCATION PROGRAM BOOK., vol. 2013, no. 1, 6 December 2013 (2013-12-06), pages 220 - 226 *
LOWENBERG, B ET AL.: "Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia.", JOURNAL OF CLINICAL ONCOLOGY., vol. 28, no. 2010, 1 October 2010 (2010-10-01), pages 4333 - 4338, XP055349035 *

Also Published As

Publication number Publication date
WO2016201365A2 (fr) 2016-12-15

Similar Documents

Publication Publication Date Title
BR112019023409A2 (pt) Métodos para tratar um câncer em um paciente e uma malignidade hematológica, para expandir linfócitos infiltrantes de tumor, linfócitos de sangue periférico e linfócitos infiltrantes de medula, processo para a preparação de uma população de linfócitos infiltrantes de tumor, e, uso de um tumor líquido na fabricação de uma população de linfócitos infiltrantes de tumor.
WO2016201365A3 (fr) Procédés pour le traitement de cancers
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2016059241A3 (fr) Produits diagnostiques et thérapeutiques pour le cancer du poumon avec mir-660
MX2018005071A (es) Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp.
CA3055791A1 (fr) Procedes de traitement
MX2022008266A (es) Metodos para el almacenamiento de sangre completa y composiciones de esta.
EP3147285A3 (fr) Composés de purinone en tant qu&#39;inhibiteurs de kinase
WO2015191934A8 (fr) Barrière hémato-encéphalique pénétrant des protéines de liaison spécifiques doubles pour le traitement de maladies cérébrales et neurologiques
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2016160621A3 (fr) Cellules nk-92 utilisées dans une polythérapie en association avec des médicaments anticancéreux
MX2019012260A (es) Metodos de analisis mutacional y de metilacion del adn para vigilancia del cancer de vejiga.
BR112017019189A8 (pt) Agente terapêutico celular para tratamento de câncer e terapia de combinação com o mesmo
WO2016130800A3 (fr) Compositions pharmaceutiques comprenant des dérivés d&#39;alcool périllylique
GB2523211A8 (en) MCT protein inhibitor-related prognostic and therapeutic methods
CN105189786A8 (zh) 用作治疗癌症的疗法的靶标的falz
WO2013188823A3 (fr) Analyses pour le pronostic du cancer
PH12020550042A1 (en) Methods of treating cancer with farnesyltransferase inhibitors
AU2014339977A8 (en) Methods of determining breast cancer prognosis
Korobeynikova et al. ABC-, VEN-and frequency analysis of treatment of Atrial Fibrillation in outcome patients
BR112018010848A2 (pt) grelin-o-acilotransferase (cabra) e usos da mesma
Sejdinovic et al. Differences in expression and prognostic values of p16 (ink) and VEGF in squamous and adenocarcinoma of the lung
WO2021013592A8 (fr) Procédé de détermination de la réponse au traitement d&#39;un patient atteint d&#39;un carcinome pulmonaire non à petites cellules (nsclc)
UA104420U (uk) Спосіб прогнозування зрощення перелому
Sun et al. D31 IMMUNE REGULATION OF SARCOIDOSIS AND INTERSTITIAL LUNG DISEASE: The Role Of Cxcl9 And Monocytes In Sarcoidosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16808472

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16808472

Country of ref document: EP

Kind code of ref document: A2